// App-Quantinova.ai

: Immuno-Genetic Changes Underlie Response to Immune Checkpoint Blockade Therapy in Richter's Syndrome Mouse Models

Researchers

Presenter

  • Elisa ten Hacken

Principal Investigators

  • Gabriela Brunsting Hoffmann

  • Kayla Cruz

  • Erin Michelle Parry

  • Elizabeth Witten

  • Donna S. Neuberg

  • Gordon J Freeman

  • Catherine J. Wu

Medical Centers

  • Department of Medicine, Brigham and Women's Hospital, Boston, MA

  • Department of Medical Oncology, Dana-farber/Boston Children's Cancer and Blood Disorders Ctr, Boston, MA

  • Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA

  • Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

  • Department of Data Science, Dana-Farber Cancer Institute, Boston, MA

  • Harvard Medical School, Boston, MA

  • Broad Institute of MIT and Harvard, Cambridge, MA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Carboxypeptidase B1

  • Bruton tyrosine kinase

  • cMYC

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • Cluster of Differentiation 4

  • Cluster of Differentiation 43

  • Cluster of Differentiation 44

  • Cluster of Differentiation 2AP

  • Cluster of differentiation 45

  • Programmed death-ligand 1

  • Cluster of differentiation 8A

  • L-selectin

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Randomized

  • Efficacy

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved